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Among the primary brain tumors, gliomas are the most commonly found. In the United States, these
tumors account for approximately 78% of the new cases of primary malignant brain and central nervous
system (CNS) tumors diagnosed annually. Glioblastoma multiforme (GBM) is the most common and
aggressive type of glioma, with the poorest survival duration. Although surgical techniques, radiotherapy
and chemotherapy have improved, the prognoses of patients with glioblastomas are still poor (~1 year),
which is largely because of the spread of tumor cells to other regions of the brain. Intravenous admin-
istration of chemotherapy drugs is the standard procedure for treat these spreaded cells, but the
treatment effect is limited because of the adverse side effect and the delivery blockage from the blood
ebrain barrier (BBB). Thus, developing an effective treatment system to conquer this blockage will be
beneﬁcial for those who suffer from malignant brain tumor.
Focused ultrasound (FUS) sonication in the presence of microbubbles (MB) may be able to promote the
effectiveness of drug delivery, and help to overcome the blockage. The oscillation and destruction of
microbubbles as well as microstreaming and radiation forces are the key factors capable of creating the
transient rupture of the vascular barriers and subsequent increase in the tumor's vascular permeability.
The success of FUS BBB disruption in delivering a variety of therapeutic molecules into brain tumors
has recently been demonstrated in an animal model. In this paper the authors review a number of critical
studies that have demonstrated successful outcomes, including enhancement of the delivery of tradi-
tional clinically used chemotherapeutic agents or application of novel nanocarrier designs for actively
transporting drugs, or extending drug half-lives to signiﬁcantly improve treatment efﬁcacy in preclinical
animal models.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gliomas are the most common of the primary brain tumors; in
the United States, they account for approximately 78% of the new
cases of primary malignant brain and central nervous system (CNS)
tumors diagnosed annually. Glioblastoma multiforme (GBM) is the
most common and aggressive glioma, with the poorest survival. It
is a highly malignant brain tumor, typically affecting adults be-
tween 45 and 60 years of age. Although surgical techniques,
radiotherapy and chemotherapy have improved, the prognoses ofrgery, Linkou Chang Gung
uan, 333, Taiwan.
ei).
ncology Society.
Society. Production and hosting bypatients with glioblastomas are still poor, largely because of the
spread of tumor cells to other regions of the brain.
The chemotherapeutic agent 1,3-bis- (2-chloroethyl)- 1-
nitrosourea (BCNU, also known as carmustine) and Temozolo-
mide (TMZ), have become commercially available to be used in the
treatment of malignant brain tumors. Although it improves patient
survival, its efﬁciency is limited by side effects such as myelosup-
pression, hepatic toxicity, and pulmonary ﬁbrosis, which increases
the difﬁculty of clinical treatment. The effect is limited because of
adverse side effect and delivery blockage from the bloodebrain
barrier (BBB). The BBB is composed of endothelial cell tight junc-
tions (zonulae occludens), basal lamina and glial processes. In
addition, endothelial cells of cerebral vessels are devoid of fenes-
trations and transendothelial channels, and have a paucity of
pinocytotic vessels. Thus, the BBB plays a protective role in the
central nervous system (CNS), restricting the movement of many
substances into the brain. Thus, developing a new brain tumorElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Y.-J. Lin et al. / Journal of Cancer Research and Practice 3 (2016) 63e6864therapeutic system precisely targeting the tumor cells is urgently
needed.
Focused ultrasound (FUS) sonication in the presence of micro-
bubbles (MB) can disrupt the BBB, increasing its permeability.1 This
type of disruption is transient and reversible, and does not damage
neural cells. The oscillation and destruction of microbubbles as well
as microstreaming and radiation forces are the key factors possible
to create the transient rupture of vascular barriers and subsequent
increase in the tumor's vascular permeability. This method could
provide a means for targeted delivery of therapeutic or diagnostic
agents to the brain.2. Focused ultrasound with chemotherapeutic agent
2.1. BCNU
In our hypothesis, transcranial focused ultrasound in the pres-
ence of microbubbles disrupted the BBB and then enhanced drug
delivery. Therefore, we implanted the cultured glioma cells in rat
brain as the tumor model. BCNU (13.5 mg/kg) was administered
intravenously. MR imaging was used to evaluate the effect of
treatments, including analysis of tumor progression and animal
survival, and brain tissues were histologically examined.1,2Fig. 1. Treatment effect of FUS-enhanced BCNU in brain tumor bearing rats. Group 1: contr
only; group 4: rats treated with BCNU enhanced by FUS.The concentration of BCNU through the BBB was enhanced both
in normal brains (by 340%) and tumor-implanted brains (by 202%)
without intracranial hemorrhage (Fig. 1). In addition, treatment of
tumor-implanted rats with focused ultra-sound alone had no
beneﬁcial effect on tumor progression.
Administration of BCNU only transiently controlled tumor pro-
gression. Nevertheless, relative to untreated controls, the duration
of animal survival was improved by treatment with BCNU alone
(increase in median survival time, 15.7%, P ¼ .023). Treatment with
focused ultrasound before BCNU administration controlled tumor
progression and improved animal survival relative to untreated
controls (increase in median survival time, 85.9%, P¼ .0015).1 These
results revealed disruption of the BBB by using focused ultrasound,
which signiﬁcantly enhances the penetration of BCNU through the
barrier. Furthermore, treatment of tumor-implanted rats with
focused ultrasound before administration of BCNU both controlled
tumor progression and improved animal survival.1,22.2. Temozolomide (TMZ)
Temozolomide (TMZ) is the most important chemotherapy
agent administered to control glioma progression. It is an alkylating
agent of the imidazotetrazine series that possesses strong anti-
neoplastic activity against high-grade glioma.3,4 TMZ is an oralol group; group 2: rats treated with ultrasound only; group 3: rats treated with BCNU
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to penetrate the BBB. However, BBB opening may help additional
TMZ to reach target area for tumor treatment. In our studies, the
therapeutic efﬁcacy of FUS-BBB opening for enhanced temozolo-
mide (TMZ) delivery in glioma treatment in a rat model showed
promising results.4 TMZ concentration in plasma and brain samples
collected at different times revealed a signiﬁcant increase as
compared with non-FUS treated groups. The local TMZ concentra-
tion increased from 6.98 to 19 ng/mg. In addition, TMZ degradation
time in the tumor core was found to increase from 1.02 to 1.56 h.
Therefore, FUS-BBB was demonstrated to enhance TMZ delivery.
Subsequently, improved tumor progression and animal survival
were found. Therefore, we established that transcranial FUS-BBB
opening enhances the delivery of small particles of chemothera-
peutic agent including of BCNU and TMZ through the BBB, there-
after enabling a targeted increase in drug dosage in the tumor
region. FUS-enhanced drug delivery signiﬁcantly suppressed tumor
growth and prolonged animal survival, suggesting that this
approach may improve future therapeutic outcomes from chemo-
therapy for brain tumors in humans.4
3. Focused ultrasound with nanoparticles
Advances in nanotechnology and molecular biology have
allowed the development of novel nanomedical platforms.2,5 The
superparamagnetic properties of magnetic nanoparticles (MNPs)
allow them to be guided by an externally positioned magnet.
However, their therapeutic use in treating CNS pathologies in vivo is
limited by insufﬁcient local accumulation and retention resultingFig. 2. (a) MRI monitoring of tumor growth in brain tumor-bearing rats. Control: rats wi
intravenous administration of MNPs immobilized BCNU, then treated FUS and MT. (beg) He
of accumulated NMPs in brain tissue. MNP: magnetic nanoparticle; FUS: focused ultrasounfrom their inability to traverse the BBB. Therefore, combined use of
focused ultrasound and magnetic targeting synergistically delivers
therapeutic MNPs across the bloodebrain barrier to enter the brain
both passively and actively. To test the effect of FUS-BBB opening for
enhanced nanoparticles (for example: MNPs, approximate 200 nm)
to penetrate to brain parenchyma, rat studies were performed. FUS
treatment alone increased local deposition of MNPs relative to the
contralateral hemisphere. Subsequently applying MT (application of
magnetic ﬁeld) caused the greatest increase in MNPs accumulation.
Treatment experiments showed that combining magnetic nano-
particles with the FUS and magnetic guidance procedure provided
the most effective means of controlling tumor progression. MRI
monitoring of the tumor size demonstrated signiﬁcant tumor
growth repression; furthermore, the MNP accumulations were
shown during pathology examination and transmission electron
microscope imaging (Fig. 2).6,7
Therefore, targeting of nanoparticles is a safe and promising
strategy for achieving localized drug delivery, even in deep-seated
brain tumors. Then, tumor progression and survival may be
improved by combined use of focused ultrasound and magnetic
nanoparticle.
4. Targeted drug delivery and nanoparticle-mediated
hyperthermia therapy
4.1. NGO as drug carriers
Malignant brain tumor consists of heterogeneous cell types
which may contribute to standard chemo/radiotherapy resistance.thout treatment; BCNU only: intravenous administration of BCNU only; experiment:
matoxylin and eosin stain of brain tissue. (h): transmission electron microscope images
d; MT: application of magnetic ﬁeld.
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that may help to clear a majority of tumor cells. To achieve such a
goal, a multi-functional drug carrier that is able to transport the
drug, be used as a gene therapy agent and serve as a hyperthermia
agent may facilitate the improved treatment effect. Among several
candidates, nanographene oxide (NGO) has the greatest potential
for nanoparticles arising from its high surface areas for carrying
various agents. NGO is widely used in biomedical applications such
as drug delivery, gene delivery, and biosensors due to its high
intrinsic mobility, thermal conductivity, mechanical stiffness,
electrical conductivity, gas barrier properties, and optical absorp-
tion in the near-infrared (NIR) region.
4.2. Gd-NGO/Let-7g/EPI
To study the potential of NGO as a multifunctional drug carrier,
contrast agent, antitumor microRNA and chemotherapeutic agent,
epirubucin were immobilized on NGOs for testing its efﬁcacy
against tumors. An MRI-detectable nanovector (Gd-NGO) was
developed to effectively load EPI and Let-7g miRNA (Gd-NGO/Let-
7g/EPI). It not only can display the area of BBB-opening via MRI R1
imaging, but also transfer the drug (EPI) and miRNA (Let-7g) into
brain tumor cells for diagnosis and dual-therapy. By application of
FUS, the NGO particles are able to penetrate into brain parenchyma,
and be visualized by MRI monitoring (Fig. 3).
4.3. PEG-NGOC225/EPI
Epidermal growth factor receptor (EGFR) is a receptor tyrosine
kinase which is overexpressed in several solid tumors including
glioma. Its upregulation is strongly correlated with cell prolifera-
tion, apoptosis, differentiation and migration. Many anti-EGFR
monoclonal antibodies such as cetuximab (C225) and pan-
itumumab (ABX-EGF) were developed based on blocking signal
transduction. Epirubicin inhibits DNA synthesis by intercalating
DNA strands and triggers DNA cleavage by topoisomerase II,
resulting in mechanisms that lead to cell death. When combined
with a nano-based delivery system, the tumor targeting efﬁcacy
could be enhanced and the toxicity reduced. We developed a new
targeted delivery system consisting of PEGylated NGO loaded with
epirubicin (EPI) and anti-EGFR antibodies (C255) (PEG-NGOC225/
EPI), designed to block EGFR growth signal, target chemotherapy,Fig. 3. NGO carried contrast agent, antitumor microRNA and epirubicin, anand mediate photothermal treatment of gliomas by near-infrared
(NIR) light.8 In a mouse-xenograft model of glioma, the coopera-
tive triple-treatment nanomedicine PEG-NGO-C225/EPI that com-
bines anti-EGFR (C225) to target malignant glioma cells and inhibit
their propagation, chemotherapeutic drug delivery to damage the
DNA of cancer cells, and photo-irradiation to burn residual tumor
cells were successfully demonstrated.8 When mice were irradiated
with NIR (2 W/cm2, 120 s) 3 days after injection of PEG-NGO-C225/
EPI, all irradiated tumors disappeared 7 days after irradiation. No
tumor regrowth was noted in this group over the course of 50 days.
4.4. NMGOemPEGeEPI
There is another nanometer-scale magnetic GO drug carrier
(NMGOemPEG) that can carry epirubicin (EPI) to form
NMGOemPEGeEPI, which could be guided by magnetic targeting
(MT) to easily reach local toxic drug concentrations of more than
14-fold higher than the surrounding tissues.9 Besides, the highly
concentrated GOs could then serve as a heat-conducting base to
trigger local temperature elevation upon application of extremely
low-power FUS (LFUS) (the power is 20- to 50-fold lower than high-
intensity FUS), resulting in deep-seated targeted hyperthermia and
drug delivery, without the current limitations of widely distributed
or low-penetrating heat sources.
In summary, the combination of targeted chemotherapeutic
agents by way of ligand-binding (anti-EGFR antibody) or environ-
mental control (magnetic ﬁeld) with nanoparticle-induced hyper-
thermia effects via laser irradiation or low-power focused
ultrasound (LFUS) were proven to be an effective weapon in
treating brain tumor in animal models without obvious systemic
toxicity. Furthermore, genetic engineering on cancer cells could
also be performed via nanoparticles. An MRI-detectable, drug and
miRNA carrying vector (Gd-NGO) was developed to effectively load
EPI and Let-7g miRNA (Gd-NGO/Let-7g/EPI) and transfer them into
cancer cells. This suggests the potential use of Gd-NGO complexes
as efﬁcient non-viral drug and gene delivery vectors for future
chemogene therapy applications.10
5. From small to large animals
Several experiments on mice successfully demonstrate the
therapeutic impact of FUS for BBB opening combined withd were designed as multifunctional drug carrier to treat brain tumors.
Fig. 4. (Left) Experimental setup showing the neuronavigation system and registration of the focal point position of the FUS transducer on the neuronavigation system. M1/
M2 ¼ markers providing spatial reference for the neuronavigation system. T ¼ FUS transducer. (Right) Images from the neuronavigation screens showing interactive positional
changes of the FUS focal beam (in red) to the planned target position (in yellow).
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to clinical application, the size of the human brainwarranted larger
FUS probe and more precise lesion localizing.
Unlike a single element transducer with ﬁxed focus at the
geometric center, an ultrasound phased array can steer the focus of
the ultrasonic energy to an arbitrary position by driving each
element with a signal of the appropriate phase. We have designed a
prototype of a 256-channel ultrasound phased-array system to
perform localized BBB disruption, which demonstrates the feasi-
bility of simultaneous, dual-frequency exposure from an ultrasound
array. The large animal (swine) experiments conﬁrmed the feasi-
bility of inducing a large BBB-opened region by electronic scanningFig. 5. Representative MR images and corresponding stained brain sections from experimen
along transverse plane, stained with Evans Blue. Stained regions indicate areas of BBB disruvia phase switching control, and also demonstrated the potential to
enhance the BBB-opening effect through dual-frequency FUS
exposure.11
6. Focused ultrasound with navigation
Focused ultrasound used in combinationwith microbubbles can
stably produce transient openings of the BBB in small animals.
Since the thickness of the skull is varied, the blockage of ultrasound
energy may be interfered with, then cause the energy lost in a
target area. To adjust the parameter to ﬁt clinical use, we chose
swine as a model to mimic the human response.tal animals. a: Coronal plane; (b) sagittal plane; (c) transverse plane; (d) brain section
ption.
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neurosurgery by providing a way to navigate through the body
using 3D images. An interface between FUS and neuronavigator
was developed to allow guidance. The accuracy of neuronavigation
in guiding FUS BBB opening was quantiﬁed by measuring the
discrepancy between the assigned and actual BBB opening location
on the focal plane. The mean distance discrepancy between the
target point and the BBB-opened location in our study was
2.3 ± 0.9 mm, which is within the acceptable range of clinical
neuronavigational guidance.
Neuronavigation-guided FUS in the swine brain has the poten-
tial to become a ﬂexible medical tool for drug delivery across the
BBB into the human brain. The application of a neuronavigation
system in guiding FUS for BBB openingwill provide a newandmore
ﬂexible route for accomplishing FUS-enhanced brain drug delivery
and is expected to speed up the translation process and widespread
use of this technology.12 The ultimate goal of this study is to
develop an innovative nanodrug-chemotherapy and thermal ther-
apy for tumor treatments using noninvasive focused ultrasound
under neuronavigator-guidance and monitoring (Fig. 4, Fig. 5).
7. Conclusion and perspective
Focal BBB disruption by FUS provides opportunities for higher
concentration of drugs such as BCNU and temozolomide to be
delivered to the target region. Besides, it can be integrated with
novel nanocarrier (MNPs) under magnetic guidance, where moni-
toring can result in not only passive diffusion but also active de-
livery. Furthermore, a triple-therapy composed of cytotoxic target
agents, chemotherapeutic agents and hyperthermia by laser or by
ultrasound (low-intensity FUS) was proven to have survival bene-
ﬁts in mouse glioma models. The potential application of gene
therapy via transferring miRNA into a tumor cell through FUS-
induced BBB opening appears promising as well. The combination
of neuronavigation and ultrasound phased array dual frequency
system on a larger animal model (eg. swine) successfully demon-
strates a precise targeted method for brain tumor treatment. Our
innovation raises the possibility of improving the therapeutic efﬁ-
cacy of chemotherapeutic agents or reducing the total dose
necessary to systemically minimize the circulation toxicity. How-
ever, further research on the toxicity of nanoparticles and theadvancement of the FUS-generating system is necessary before any
effective clinical applications are generated.Conﬂict of interest
There is no conﬂict of interest for all authors.References
1. Liu HL, Hua MY, Chen PY, et al. Blood-brain barrier disruption with focused
ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma
treatment. Radiology. 2010;255:415e425.
2. Yang HW, Hua MY, Hwang TL, et al. Non-invasive synergistic treatment of brain
tumors by targeted chemotherapeutic delivery and ampliﬁed focused
ultrasound-hyperthermia using magnetic nanographene oxide. Adv Mater.
2013;25:3605e3611.
3. Liu HL, Yang HW, Hua MY, et al. Enhanced therapeutic agent delivery through
magnetic resonance imaging-monitored focused ultrasound blood-brain bar-
rier disruption for brain tumor treatment: an overview of the current pre-
clinical status. Neurosurg Focus. 2012;32:E4.
4. Wei KC, Tsai HC, Lu YJ, et al. Neuronavigation-guided focused ultrasound-
induced blood-brain barrier opening: a preliminary study in swine. Am J
Neuroradiol. 2013;34:115e120.
5. Chen PY, Liu HL, Hua MY, et al. Novel magnetic/ultrasound focusing system
enhances nanoparticle drug delivery for glioma treatment. Neuro-Oncology.
2010;12:1050e1060.
6. Wei KC, Chu PC, Wang HY, et al. Focus ultrasound-induced blood-brain barrier
opening to enhance temozolomide delivery for glioblastoma treatment: a
preclinical study. PLoS One. 2013;8:e58995.
7. Liu HL, Jan CK, Chu PC, et al. Design and experimental evaluation of a 256-
channel dual-frequency ultrasound phased-array system for transcranial
blood-brain barrier opening and brain drug delivery. IEEE Trans Biomed Eng.
2014;61:1350e1360.
8. Yang HW, Lu YJ, Lin KJ, et al. EGFR conjugated PEGylated nanographene oxide
for targeted chemotherapy and photothermal therapy. Biomaterials. 2013;34:
7204e7214.
9. Liu HL, Hua MY, Yang HW, et al. Magnetic resonance monitoring of focused
ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to
the brain. Proc Natl Acad Sci U. S. A. 2010;107:15205e15210.
10. Yang HW, Huang CY, Lin CW, et al. Gadolinium-functionalized nanographene
oxide for combined drug and microRNA delivery and magnetic resonance
imaging. Biomaterials. 2014;35:6534e6542.
11. Liu HL, Chen PY, Yang HW, et al. In vivo MR quantiﬁcation of super-
paramagnetic iron oxide nanoparticle leakage during low-frequency-
ultrasound-induced blood-brain barrier opening in swine. J Magn Reson Im-
aging. 2011;34:1313e1324.
12. Liu HL, Huang CY, Chen JY, et al. Pharmacodynamic and therapeutic investi-
gation of focused ultrasound-induced blood-brain barrier opening for
enhanced temozolomide delivery in glioma treatment. PLoS One. 2014;9:
e114311.
